BioCentury
ARTICLE | Financial News

Arvinas looking to raise $100M in IPO

August 30, 2018 7:59 PM UTC

Protein degradation company Arvinas LLC (New Haven, Conn.) filed to raise up to $100 million in an IPO on NASDAQ underwritten by Goldman Sachs, Citigroup and Piper Jaffray.

Arvinas is developing small molecules based on its Proteolysis Targeting Chimeras (PROTAC) platform, which is designed to create three-part compounds. Each comprises one molecule that binds a target, a second molecule that mediates ubiquitination and a chemical linker connecting the two. The compound forms a transient interaction with its target protein, tags it for proteasomal degradation, and then moves on to the next molecule (see "Down the Hatch")...